NextHealth S.A.

Research site

Greece Marias Kallas 11 And Gravias 2, 546 35 Thessaloniki, Greece

7 trials recruiting
Obesity · Overweight · Osteoarthritis
Adult patients

About Specializations

NextHealth S.A. in Thessaloniki, Greece specialises in clinical trials of conditions such as Obesity, Overweight, Osteoarthritis, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Nutritional and Metabolic Diseases

The Department of Endocrinology, Metabolism & Diabetes at NextHealth S.A. conducts studies on overweight or obesity and knee osteoarthritis, testing new interventions to promote weight loss and relieve joint pain.

Weight management strategies for excess body weight
Pain reduction approaches for knee osteoarthritis
Interaction between metabolic health and joint function

The research site located in Thessaloniki, Greece supports patients seeking innovative treatments for metabolic and musculoskeletal conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Marias Kallas 11 And Gravias 2546 35 ThessalonikiGreece

Open in maps ↗

Recruiting now: 7 trials
Conditions studied: 8

More sites in Thessaloniki Greece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

8 clinical trials

Obesity+1

Recruiting

Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

Registered drug

Efficacy and safety of oral semaglutide for weight loss in adults with overweight or obesity

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Systemic scleroderma

Recruiting

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Nemolizumab
Sponsor:Galderma S.A.

Contact Research Centre

Obesity+2

Recruiting

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity+2

Recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Type 2 diabetes mellitus

Recruiting

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites